期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PEG化隐形纳米脂质体的研究进展 被引量：4

Recent Development of PEGylation Stealth Nano-Liposomes
在线阅读 下载PDF
导出
摘要 PEG化隐形纳米脂质体作为一种新型药物载体,由于其特殊的体内作用特点,和普通脂质体相比具有长效、靶向、高效、低毒等优点,已在靶向制剂、控释制剂等领域中得到广泛应用。本文重点围绕PEG化隐形纳米脂质体的药动学、组织分布、提高肿瘤靶向性、降低药物毒性等方面对其近年来在药物转运系统中的研究与应用做一综述。 PEGylation stealth nano-liposomes as a novel drug delivery carrier has the advantages of long-term,targeting,high efficiency and low toxicity,compared with conventional liposomes,and has been widely applied in targeting preparations,modified-release preparations,etc.The applications of PEGylation stealth nano-liposomes including pharmacokinetics,tissue distribution,reducing toxicity and enhancing tumor targeting were reviewed in this paper.
作者 顾芃 陈建明
机构地区 第二军医大学药学院药剂教研室
出处 《药学与临床研究》 2011年第1期47-50,共4页 Pharmaceutical and Clinical Research
基金 上海市科学技术委员会纳米专项基金项目(No.0952nm03000)
关键词 隐形纳米脂质体 药动学 组织分布 肿瘤靶向性 毒性 Stealth nano-liposomes Pharmacokinetics Tissue distribution Tumor targeting Toxicity
分类号 R944.9 [医药卫生—药剂学] TQ460.6 [化学工程—制药化工]
  • 相关文献

参考文献28

  • 1Wang HJ,Zhao PQ,Liang XF,et al.Folate-PEG coated cationic modified chitosan-cholesterol liposomes for tumor-targeted drug delivery[J].Biomaterials,2010,31(14):4129-38.
  • 2Song SX,Liu D,Peng JL,et al.Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo[J].FASEB J,2009,23(5):1396-404.
  • 3Jung SH,Jung HS,Seong H,et al.Polyethylene glycolcomplexed cationic liposome for enhanced cellular uptake and anticancer activity[J].Int J Pharm,2009,382 (1-2):254-61.
  • 4Hong MH,Zhu SJ,Jiang YY,et al.Novel anti-tumor strategy:PEG -hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles[J].J Control Release,2010,141 (1):22-9.
  • 5Orditura M,Quaglia F,Morgillo F,et al.Pegylated liposomal doxorubicin pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity[J].Oncol Rep,2004,12 (3):549-56.
  • 6Dadashzadeh S,Vall AM,Rezaie M.The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats[J].Int J Pharm,2008,353 (2):251-9.
  • 7张自强,覃斌,李战,姚静.mPEG-DSPE修饰的紫杉醇脂质体的制备及其药动学研究[J].中国药学杂志,2008,43(3):199-202. 被引量：17
  • 8Yang T,Choi MK,Cui FD,et al.Preparation and evaluation of paclitaxel -loaded PEGylated immunolip osome[J].J Control Release,2007,120(3):169-77.
  • 9Ryo S,Tomoko T,Yasubiro K,et al.Effective antitumor activity of oxaliplatin encapsulated in transferring -PEG-liposome[J].Int J Pharm,2008,346(2):143-50.
  • 10Phan G,Herbet A,Cholet S,et al.Pharmacokinetics of DTPA entrapped in conventional and long-circulating liposomes of different size for plutonium decorporation[J].J Control Release,2005,110(1):177-88.

二级参考文献22

  • 1孙萍,邓树海,于维萍.PEG修饰大蒜素长循环脂质体的制备及药物动力学研究[J].实用心脑肺血管病杂志,2006,14(6):454-456. 被引量：14
  • 2梅林,孙洪范,宋存先.紫杉醇制剂研究进展[J].中国药学杂志,2006,41(18):1366-1370. 被引量：16
  • 3张晓静,张频.紫杉醇新剂型的开发及临床研究进展[J].癌症进展,2007,5(1):66-72. 被引量：57
  • 4Jang SH,Wienties MG,Lu D,et al.Durg delivery and transport to solid tumors[J].Pharm Res,2003,20(12):1337.
  • 5Li YP,Pei YY,Zhou ZH,et al.PEGylated polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers[J].J Control Rel,2001,71(3):287.
  • 6Li YP,Pei YY,Zhou ZH,et al.Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers:pharmacokinetics and antitumor effects[J].Biol Pharm Bull,2001,24(6):662.
  • 7Shenderova A,Burke T,Schwendeman S.Stabilization of 10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles[J].Pharm Res,1997,14(10):1406.
  • 8Shenderova A,Burke T,Schwendeman S.The acidic microclimate in poly (lactide-co-glycolide) microspheres stabilizes camptothecins[J].Pharm Res,1999,16(2):241.
  • 9Bazile D,Prud' Homme C,Bassoulet MT,et al.Stealth PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system[J].J Pharm Sci,1995,84(4):493.
  • 10Gabizon AA.Liposome circulation time and tumor targeting:implications for cancer chemotherapy[J].Adv Drug Deliv Rev,1995,16(2):285.

共引文献30

同被引文献32

  • 1周景润,辛梅华,李明春,顾丹丹.O-季铵盐-N,N-双长链烷基壳聚糖的制备及其性能[J].化工进展,2008,27(10):1654-1658. 被引量：11
  • 2刘扬,吕万良,张强.脂质体及纳米粒药物递送系统的研究进展[J].中国医学科学院学报,2006,28(4):583-589. 被引量：22
  • 3Siegel R, Desantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012 [J]. CA Cancer J Clin, 2012, 62 (4) : 220-241.
  • 4Ibrahim A, Hirschfeld S, Cohen MH, et al. FDA drug approval summaries: oxaliplatin [J]. Oncologist, 2004, 9 (1): 8-12.
  • 5Grolleau F, Gamelin L, Boisdron-Celle M, et al. A possible explanation for a neurotoxie effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels[J]. J Neurophysiol, 2001, 85 (5) : 2293-2297.
  • 6Cavaletti G, Tredici G, Petruccioli MG, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat [J]. Eur J Cancer, 2001, 37 (18): 2457-2463.
  • 7Krishnan AV, Goldstein D, Friedlander M, et al. Oxaliplatin and axonal Na+ channel function in vivo [J]. Clin Cancer Res, 2006, 12 (15) : 4481-4484.
  • 8Ehrsson H, Wallin I, Yachnin J. Pharmacokinetics of oxaliplatin in humans [J]. Med Oncol, 2002, 19 (4) : 261-265.
  • 9国家约典委员会编.曰家蓟舳标准新约转正标水笫35册[S].北京:化学工业出版社,2004.
  • 10Delord JP, Umlil A, Guimbaud R, et al. Population pharmacokinetics of oxaliplatin [J]. Cancer Chemother Pharmacol, 2003, 51 (2) : 127-131.

引证文献4

二级引证文献8

药学与临床研究
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部